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Abstract Recent data in the literature suggest hat the HIV-1 
Tat(I-86) protein exhibits immunosuppressive effects. Moreover, 
Tat was found to interact with dipeptidyl peptidase IV (DP IV), 
which is identical to the T cell activation marker CD26. Here we 
show that the N-terminal amino acid sequence of Tat is essential 
for the inhibition of DP IV-catalyzed IL-2(1-12) degradation. N- 
terminal modification of Tat with rhodamine prevented inhibition 
of enzymatic activity of DP IV as well as suppression of DNA 
synthesis of mitogen-stimulated human T cells. Moreover, 
natural peptides containing the X-X-Pro N-terminal motif of 
Tat also inhibited DP IV activity. These data suggest the 
existence of endogenous immunomodulatory oligopeptides which 
influence immune cell proliferation and differentiation via DP IV 
a~ does HIV-1 Tat. 
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1. Introduction 
The 86 amino acid long Tat protein of human immunode- 
fi,:iency virus type-1 (HIV-1) is a transactivator regulating the 
tlanscription of HIV genes and is essential for viral replication 
ii vitro [1,2]. Evidence exists that Tat also occurs extracellu- 
larly. HIV-1 infected T cells release Tat into the extracellular 
medium [3,4]. Extracellular Tat has been shown to suppress 
autigen as well as anti-CD3-induced activation of human T 
ctlls [5,6]. 
CD26 (dipeptidyl peptidase IV, DP IV, EC 3.4.14.5) is an 
a~tivation marker of T and B lymphocytes and of NK cells 
~ith peptidase activity [7 11]. It removes N-terminal dipep- 
tides from oligopeptides with unsubstituted N-termini, if the 
pt~nultimate amino acid is proline or alanine. However, pep- 
tides with an additional proline in the third position are re- 
si ;tant to cleavage. Data from several groups have shown a 
k~y role of DP IV in the regulation of differentiation and 
gTowth of lymphocytes. Specific inhibitors of DP IV sup- 
p essed mitogen- and alloantigen-induced T cell proliferation, 
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A,breviations. Boc, t-butyloxycarbonyl; Fmoc, 9-fluorenylmethyl- 
o~ycarbonyl; PWM, pokeweed mitogen; ACTH, adrenocorticotropic 
h~,rmone; GRP, gastrin-releasing peptide. 
cytokine production, B cell differentiation, and immunoglobu- 
lin secretion [12-17]. However, the function of DP IV in the 
proliferation and differentiation processes has not been re- 
solved yet. Of special interest was the recent finding that 
HIV-1 Tat binds with high affinity to CD26 and inhibits the 
cleavage of the synthetic DP IV substrate Gly-Pro-pNA 
[18,19]. This suggests that the immunosuppressive effects of 
Tat could be mediated by DP IV. 
In the current paper we demonstrate hat Tat(1 86) inhibits 
DP IV-catalyzed cleavage of IL-2(1-12) and suppresses DNA 
synthesis of PWM-stimulated T cells. Our data suggest hat 
the N-terminal sequence of Tat is essential for these effects. 
Since other peptides containing the N-terminal X-X-Pro se- 
quence of Tat also inhibit DP IV we assume the existence of 
endogenous DP IV inhibitors regulating DP IV activity and 
cell proliferation. 
2. Materials and methods 
2.1. DP IV and synthetic DP IV inhibitor 
DP IV (porcine kidney) was kindly provided by Dr. H.U. Demuth 
(Hans-Kn611-Institute Jena, BMFT-Group Halle, Germany). For the 
synthesis of the DP IV inhibitor Lys[Z(NO2)]-thiazolidide Boc- 
Lys[Z(NO2)]-OH was coupled with thiazolidine [14]. 
2.2. Peptides 
Human IL-2(1 12), Met-IL-2(l~6), Met-lL-2(1-12), Met-IL-2(1- 
24), IL-l[~(1-6), murine IL-6(1-12), Phe-Ala-Pro-Ala-Gly-Ala-Phe, 
and Val-Lys-Pro-Phe-Tyr were synthesized by solid-phase peptide 
synthesis with Fmoc technique using the peptide synthesizer 431A 
(Applied Biosystems). The HIV-1 Tat(I-86), Tat(l-9) were synthe- 
sized on polyoxyethylene-polystyrene graft resin in a continuous 
flow instrument constructed and operated as described by Frank 
and Gausepohl [20]. For rhodamine labeling the resin-bound N-term- 
inal free Tat(I-72) and Tat(l-9) were incubated with a 3-fold excess 
of 5-(and-6)-carboxytetramethylrhodamine succinimidyl ester (MoBi- 
Tec, G6ttingen, Germany) in the presence of PyBop (benzotriazole-1- 
yloxytripyrrolidinophosphonium hexafluorophosphate) and N-methyl- 
morpholine. The synthetic peptides were purified by reversed-phase 
HPLC and characterized by mass spectrometry. 
Xenopsin-related peptide II, [Lys°,Ala3]-bradykinin, neuromedin N, 
ACTH(34-39), and Ala-Arg-Pro-Ala-Lys were purchased from Saxon 
Biochemicals GmbH (Hannover, Germany). Met-Lys-bradykinin, hu- 
man peptide YY(3-36), porcine gastrin-releasing peptide(14-27), Ala- 
Ala-Pro-Ala, Gly-Gly-Pro-Ala, and tuftsin were obtained from Ba- 
chem (Heidelberg, Germany). 
2.3. DP IV-catalyzed hydrolysis of oligopeptides 
The effects of non-substrate p ptides on the enzymatic activity of 
DP IV were tested using human IL-2(1 12), IL-113(1-6), and murine 
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IL-6(1-12) as substrates. After preincubation (30 min, 37°C) of 550 
fkat DP IV in 1 /.tl 10 mM sodium phosphate assay buffer, pH 7.4, 
with 2 ~tl of the putative inhibitory peptide in assay buffer the enzy- 
matic reaction was started by addition of 2 ~tl of 1 mM substrate in 
assay buffer. Samples were incubated for 30 min at 37°C. Thereafter, 
the reaction was stopped by addition of 2 Ixl 30 mM phosphoric acid. 
Degradation of DP IV peptide substrates was measured by the 
method of free zone capillary electrophoresis u ing Biofocus 3000 
system of Biorad (Miinchen, Germany). Separations were performed 
as described by Reinhold et al. [19]. 
2.4. Preparation of T cells and proliferation assay 
T cells were separated from heparinized blood of healthy donors as 
described in [21]. Monocytes and B cells were depleted by passage 
through nylon wool columns (Polysciences, Warrington, USA). Pur- 
ified T-lymphocytes (95% T cells, 105 cells/100 ~tl per well) were sus- 
pended in serum-free CG-medium (Vitromex, Vilshofen, Germany) 
and stimulated with pokeweed mitogen (PWM, 2 Ixg/ml; Serva, Hei- 
delberg, Germany) in the presence ofTat(I-86), rhodamine-Tat(1-72) 
or Lys[Z(NO2)]-thiazolidide. After 90 h the cultures were pulsed for 
an additional 6h with [3H]methylthymidine (0.2~tCi per well; Amer- 
sham, Braunschweig, Germany). The cells were harvested onto glass 
fiber filters, and the incorporated radioactivity was measured by scin- 
tillation counting. 
3. Resu l ts  
3.1. Inhibition of DP IV-catalyzed IL-2(1-12) degradation by 
HIV-1 Tat(1~86) 
In the classical DP IV assay the cleavage of small synthetic 
chromogenic substrates (e.g, Gly-Pro-pNA) was spectropho- 
tometrically measured. Gutheil et al. observed that HIV-1 
Tat(I-86) inhibits DP IV-catalyzed cleavage of Ala-Pro- 
pNA [18]. Based on the method of capillary electrophoresis 
we established an alternative DP IV assay, which allows the 
use of oligopeptides analogues to N-terminal X-Pro sequences 
of potential physiologic substrates [22]. In Fig. I(A,B) the DP 
IV-catalyzed egradation of IL-2(1-12) is shown. The addi- 
tion of 40 ~tM HIV-1 Tat(i-86), a 10-fold lower concentration 
compared to the substrate, markedly inhibited IL-2(1-12) 
cleavage (Fig. 1C,D). In seven independent experiments, Tat 
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inhibited 61 + 12% of IL-2(1-12) degradation i sodium phos- 
phate buffer without NaC1. Similar results were obtained with 
the DP IV substrates IL-11](1-6) and murine IL-6(1-12) (data 
not shown). The same Tat concentration also inhibited DP 
IV-catalyzed egradation of IL-2(1-12) in the presence of 40 
and 140 mM NaC1 (41 +8 and 21 + 10% inhibition, respec- 
tively). 
3.2. Importance of the N-terminus of Tat for the inhibition of 
DP IV 
Interestingly, N-terminal modified rhodamine-Tat(1 72) 
had no effect on IL-2(1-12) cleavage by DP IV (Fig. 2). The 
short N-terminal part, Tat(I-9), in a 10-fold higher concen- 
tration than Tat(I-86), inhibited DP IV, whereas rhodamine- 
Tat(l-9) again had no effect. 
3.3. Effects of Tat(1~86) and N-terminal modified rhodamine- 
Tat(I-72) on proliferation of PWM-stimulated T cells 
To investigate whether the N-terminus i also crucial for the 
immunosuppressive action of the Tat protein, we tested the 
effects of the natural Tat(i-86) and the N-terminal modified 
rhodamine-Tat(1-72) on the proliferation of purified human T
cells after stimulation with PWM. We observed a decrease in 
the DNA synthesis down to 58 + 5% of the control with 1 I.tM 
Tat, the highest concentration used (Fig. 3). Lys[Z(NO2)]- 
thiazolidide, a highly specific inhibitor of DP IV 
(IC50 = 2.7 + 0.3 IxM [14]), exerts similar effects in the same 
concentration range. As expected, the N-terminal modified 
rhodamine-Tat(1-72) had no effect on the DNA synthesis of 
PWM-stimulated T cells. Similar effects were observed with 
PWM-stimulated human peripheral blood mononuclear cells 
(data not shown). 
3.4. Inhibition of DP IV catalyzed IL-2(1-12) cleavage by 
oligopeptides containing N-terminal X-X-Pro motif 
During the search for putative ndogenous DP IV inhibi- 
tors we focused on peptides with similarities to Tat(I-9). In-  
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Fig. 1. Influence of HIV-1 Tat(1 86) on DP IV-catalyzed IL-2(1-12) degradation. Samples were applied to free zone capillary electrophoresis. 
Absorbance was detected at 200 nm. In (A,B) the electropherograms show IL-2(1-12) and its cleavage products after 30 min incubation of 400 
HM IL-2(1-12) in the absence and presence of DP IV. 200 ~tm His was added as internal standard. In (C,D) incubations were performed in the 
presence of 40 ~tM Tat(1 86). 
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1-g. 2. Effects of Tat(l-9) and of the N-terminal modified Tat pep- 
tidies rhodamine-Tat(1-72) and rhodamine-Tat(1-9) on the inhibition 
ol DP IV catalyzed IL-2(1-12) degradation. The enzymatic activity 
as measured as described in section 2. The inhibition is equal to 
tDe difference of the residual activity (in per cent of the control) 
fi3m 100. N indicates the number of independent experiments, each 
bring carried out in triplicate. Data are expressed as mean inhibi- 
ti )n + S.D. 
deed, other peptides with the N-terminal X-X-Pro-motif of 
]at  are also capable of inhibiting DP IV catalyzed IL-2(1 
1 ~) degradation (Fig. 4). The non X-X-Pro-peptide Met-Lys- 
b-adykinin had no effect on IL-2(1-12) degradation. All in- 
h bitory X-X-Pro-peptides found are greater than 6 amino 
acids in length. The tetra-, penta- and hexa-X-X-Pro-peptides 
u~ed did not inhibit DP IV. X-X-Pro-peptides with 7 up to 34 
a,nino acids applied in equimolar concentration to the sub- 
s~rate (400 p.M) exerted 30-70% inhibition of IL-2(1-12) de- 
gradation. Tat consisting of 86 amino acids was the most 
p)tent, since a 10-fold lower concentration inhibited 
61 _+ 12% of IL-2(1-12) degradation. 
4 Discussion 
Even early in infection, the lymphocytes of HIV-1 positive 
iT dividuals exhibit a defect in their response to soluble anti- 
gens [23]. Recently, it was shown that the Tat protein of HIV- 
1 formerly known as a transcription activator, also exerts 
iramunosuppressive eff cts. In cell culture, it suppressed anti- 
g~m-induced proliferation of human T lymphocytes [5]. Inter- 
e~tingly, Gutheil et al. have shown that Tat binds to CD26, an 
a~;tivation marker of T lymphocytes identical with dipeptidyl 
p,~ptidase IV (DP IV) [18]. With the small synthetic Gly-Pro- 
p~A substrate for DP IV they observed that Tat is a strong 
i] hibitor of DP IV, at least at low salt concentrations. Cur- 
i(usly, the inhibition of the Gly-Pro-pNA degradation by Tat 
is salt-dependent. With the data at 0 and 40 mM NaC1, 
(,utheil et al. proposed that Tat does not inhibit the activity 
o" DP IV at physiological salt concentrations. 
We established a DP IV assay, which exploits the sensitivity 
o" capillary electrophoresis and allows the use of N-terminal 
o igopeptides of putative physiological DP IV substrates, e.g. 
I1,-2(1-12). At low salt concentrations, which are preferred 
ft,r capillary electrophoresis, 40 I.tM Tat inhibits 61 + 12% of 
I1,-2(1-12) degradation. In accordance with Gutheil et al. we 
observed a decreased inhibitory effect of Tat at 40 mM NaC1 
[18]. However, at 140 mM NaC1, we still observed inhibition 
o '  21 _+ 10% of IL-2(1-12) degradation with the same Tat con- 
ccntration. This suggests that Tat binds to DP IV at physio- 
legical salt conditions and that it is a natural inhibitor of DP 
i--~ r. 
CD26 expression on T and B lymphocytes and on NK cells 
was shown to be dependent on their activation status. Inter- 
estingly, specific inhibitors of DP IV suppressed mitogen- 
stimulated T cell proliferation and modulated cytokine pro- 
duction [21]. In cultures of the histiocytic U937-H cell line, 
which express high levels of DP IV, DP IV inhibitors also 
decreased DNA synthesis and modulated cytokine produc- 
tion, whereas they had no effect on U937-L cells, which ex- 
press low levels of DP IV [24]. Recently, we demonstrated that 
Tat also suppressed DNA synthesis of U937-H cells and in- 
fluenced cytokine production in the same manner as that of 
synthetic DP IV inhibitors [19]. These data provide evidence 
that DP IV plays a crucial role in the regulation of activation 
and proliferation, not only of T lymphocytes, but also of 
other cells and that DP IV is involved in the mediation of 
Tars immunosuppressive activity. 
Several investigators e tablished anti-proliferative effects of 
Tat on antigen-induced lymphocyte proliferation [5,6], but 
also reported that Tat had no effect on phytohemagglutinin- 
induced T cell proliferation. In contrast, synthetic DP IV in- 
hibitors suppressed antigen-induced as well as mitogen-in- 
duced T cell proliferation. To test our hypothesis that Tat 
acts via DP IV inhibition, we examined effects of Tat on 
PWM-stimulated human peripheral blood mononuclear cells 
(PBMC) and on human T lymphocytes. In both cell systems 
we observed ecreased DNA synthesis in the presence of Tat. 
Tat was as potent as the synthetic DP IV inhibitor Lys- 
[Z(NO2)]-thiazolidide (IC~0 = 2.7 + 0.3 ~tM [14]). These results 
confirm that Tat's immunosuppressive eff cts on T lympho- 
cytes could be mediated by an interaction with DP IV. The 
existence of a viral immunomodulatory oligopeptide implies 
the existence of an endogenous counterpart. In further studies, 
we looked for the part of the Tat protein which mediates the 
inhibitory action on DP IV. N-terminal modified rhodamine- 
Tat(I-72) has lost the ability to inhibit DP IV-catalyzed 
IL-2(1 12)degradation as well as to suppress mitogen-induced 
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Fig. 3. Influence of Tat(I-86) (l), rhodamine-Tat(1-72) (A , and 
Lys[Z(NO2)]-thiazolidide (I) on DNA synthesis of PWM stimulated 
purified T cells. Purified T ceils (95%, 106 cells/ml) were incubated 
with PWM (2 ktg/ml) in presence of Tat(I-86), rhodamine-Tat 
(1-72), or Lys[Z(NO2)]-thiazolidide in the indicated concentrations. 
After 90 h, the cultures were pulsed with [ZH]methylthymidine 
([*H]TdR) for an additional 6 h. [3H]TdR incorporations in cpm 
are indicated as mean + S.D. from 4 different experiments. The val- 
ues are expressed as% [3H]TdR incorporated related to control cul- 
tures without effectors ([3H]TdR incoporation in control cultures: 
65 600 + 8400 cpm). 
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Peptide N-Terminus Length 
AAPA AAgA 4 
GGPA GGgA 4 
Tuftsin TKPR 4 
VKPFY VKPFY  5 
ARPAK AR~AK 5 
ACTH(34-39) AFPLE  F 6 
NeuromedinN KIgY I  L 6 
FAPAGAF FAgAG AF 7 
M-IL-2(1-6) MAPTS SS 7 
Xen.-rel. Peptide II FHgKR PWIr, 9 
Tat(l-g) MDgVD PNIE  9 
[K°,A3]-Bradykinin KRgAG FSPFR 10 
M-IL-2(1-12) HAgTS SSTK... 13 
GRP(14-27) MYgRG NHWA... 14 
M-IL-2(1-24) NAgTS SSTK... 25 
Peptide YY(3-36) IKgEA PGED... 34 
MK-Bradykinin MKRPP GFSP... 11 
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Fig. 4. Influence of X-X-Pro-peptides on DP IV catalysed IL-2(1-12) degradation. 400 pM IL-2(1-12) was incubated with DP IV for 30 min in 
the presence of 400 p.M X-X-Pro-peptide. 400 IxM MK-bradykinin was used as control. The N-terminal amino acid sequences are written in 
single-letter code. The error bars indicate the standard eviation of N different experiments, each performed in triplicate. ACTH, adrenocortico- 
tropic hormone; Xen.-rel. peptide II, xenopsin-related peptide II; GRP, gastrin-releasing peptide. 
PBMC or T cell proliferation. Since the short N-terminal part 
Tat(l-9) also inhibited DP IV, whereas N-terminal modified 
rhodamine-Tat(1-9) had no effect, the N-terminal structure of 
the Tat protein seemed to be important for the inhibition of 
DP IV. Interestingly, X-X-Pro-peptides other than Tat(l-9) 
also inhibited DP IV. The extent of inhibition depends on 
the length o f  these peptides: All inhibitory X-X-Pro-peptides 
found are longer than 6 amino acids and Tat consisting of 86 
amino acids was the most potent. Two of the inhibitory X-X- 
Pro-peptides are peptide YY(3-36), which results from the 
claevage of peptide YY by DP IV, and gastrin-releasing pep- 
tide (14-27). The consequences of our findings for the gastro- 
intestinal system remain to be investigated. 
Interestingly, some cytokines and cytokine precursors con- 
tain many prolines near the N-terminus [25]. Erythropoietin, 
IL-6 and TGF-J31-prepropeptide ar  X-X-Pro-peptides and G- 
CSF, IL-lct-precursor, IL-11~-precursor, LIF, lymphotoxin- 
precursor and IL-13 are putative substrates for DP IV that 
release X-X-Pro-peptides after cleavage of the N-terminal X- 
Pro- or X-Ala-dipeptide. Our results raise the possibility that 
DP IV-mediated effects on the proliferation and differentia- 
tion of activated T-lymphocytes and of other cells expressing 
DP IV, e. g. U937-H cells, could be regulated by endogenous 
peptides. Furthermore, we obtained evidence that the immu- 
nosuppressive effects of the HIV-1 Tat protein were mediated 
by CD26/DP IV. Thus, CD26-Tat interactions may play a 
crucial role in the development and progression of HIV 
mediated AIDS disease. 
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